@Qazulight@PeptideBase retatrutide improves mitochondrial function and triggers mitochondrial biogenesis (the creation of new mitochondria), which is central to how it burns fat. So, it actively rebuilds your cellular energy infrastructure: https://t.co/7XEye40puh
If your goal is building muscle (or preserving it while getting lean), Retatrutide is significantly better than Tirzepatide.
AKA EAT MORE FOOD THAN YOU THINK YOU CAN.
*****Here’s why the triple agonist beats the dual agonist when MUSCLE is the priority*****
The Glucagon Advantage-beating a dead horse
Tirzepatide = GLP-1 + GIP
Retatrutide = GLP-1 + GIP + Glucagon
The addition of glucagon receptor agonism is the game changer. Glucagon increases energy expenditure and promotes fat breakdown while being more muscle-sparing than pure GLP-1 agonism.
Better Body Recomposition-
Because Retatrutide ramps up metabolic rate more AGGRESSIVELY you can often eat MORE food while still losing fat. More food = more nutrients and amino acids available for muscle growth and recovery.
Tirzepatide is excellent at fat loss, but it tends to be more catabolic on muscle when calories get too low.
Lean Mass Retention-
Early data and real-world use show that Retatrutide generally preserves (and in some cases supports) lean mass better than Tirzepatide during aggressive fat loss phases. The glucagon effect appears to help counteract some of the muscle loss commonly seen with strong GLP-1 drugs.
Nutrient Partitioning & Training-
Retatrutide’s higher energy expenditure can improve how your body partitions nutrients — directing more toward muscle when you’re training hard, especially when stacked with things like TRT and HGH.
This makes it more “recomp-friendly” than Tirzepatide for people who want to get lean while building or maintaining muscle.
Bottom line:
• Fat loss only → Tirzepatide is still very strong.
• Fat loss + muscle building/preservation → Retatrutide is clearly superior right now.
Retatrutide's liver data is unlike anything we've seen from a weight loss drug:
- 86% liver fat reduction at 48 weeks, most of it within the first 24 weeks
- 93% of patients achieved completely normal liver fat levels
For context, tirzepatide reduces liver fat by 45–57%.
One in three adults has fatty liver disease and most don't know it.
The reason for this is retatrutide's glucagon receptor. It tells the liver directly to burn its stored fat, not just reduce calories coming in.
@rorynotsorry Hi @rorynotsorry , I’m from
Chile, I just ordered from your shop and it says was already shipped. However, the USPS site says the tracking is not available. I need help!🙏🏼
Excellent video from Jeff Nippard right here
Reiterating:
If you want to grow your Calves…STOP going all the way up onto your toes
Raise only to neutral foot and then come back down
Bias your time heavily toward the bottom stretched (dorsiflexed) position
🚨 LILLY WANTS TO KILL AFFORDABLE RETATRUTIDE.
The whole story, and why you should care 👇
Right now Eli Lilly is in court fighting to reclassify retatrutide as a "biologic." If they win, the drug gets locked behind a 12-year wall and compounded reta is gone for good.
And the whole thing hinges on TWO amino acids.
Reta is a 39-amino-acid peptide. Anything over 40 gets classified as a biologic instead of a regular drug. Lilly wants 2 extra tacked-on amino acids counted so it crosses that line.
Why fight this hard over what's basically a rounding error?
🔒 Biologic = 12 years of market exclusivity vs 5 for a normal drug
🔒 Biologic = permanently ineligible for compounding (no compounded reta, ever)
🔒 Biologic = years longer before Medicare can negotiate the price, while taxpayers foot the bill
There's also a quieter motive: reta is stronger than tirzepatide (Mounjaro/Zepbound). Locking it up protects Lilly's blockbuster from getting cannibalized by its own better drug.
Two amino acids should not decide whether millions can afford treatment.
📣 Tell your Reps and Senators to pay attention to this case. Find yours: https://t.co/izrpOlOcCw
@LillyPad@a4pcrx@US_FDA@hubermanlab@thegarybrecka
Hemos realizado una revisión de mesas y actas de la última elección, sobre la base de la información remitida por nuestros apoderados de mesa. Han habido denuncias de irregularidades puntuales, pero nuestra auditoria confirma la integridad, en general, del proceso electoral. Quiero agradecer a nuestros apoderados y dejarlos comprometidos a seguir velando en futuras elecciones por la transparencia de las mismas.